105
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Noninvasive Methods for Detecting Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B: A Single-Center Retrospective Study

, , , &
Pages 6323-6331 | Received 17 Jun 2023, Accepted 14 Sep 2023, Published online: 25 Sep 2023

References

  • Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555. doi:10.1016/S0140-6736(15)61412-X
  • Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–2219. doi:10.1016/j.vaccine.2011.12.116
  • Lampertico P, Agarwal K, Berg T. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
  • Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–1665. doi:10.1200/JCO.2009.26.2675
  • Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
  • Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495–500. doi:10.1056/NEJM200102153440706
  • Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134(6):1670–1681. doi:10.1053/j.gastro.2008.03.001
  • Shackel NA, McCaughan GW. Liver biopsy: is it still relevant? Intern Med J. 2006;36(11):689–691. doi:10.1111/j.1445-5994.2006.01210.x
  • Yoshioka K, Kawabe N, Hashimoto S. Transient elastography: applications and limitations. Hepatol Res. 2008;38(11):1063–1068. doi:10.1111/j.1872-034X.2008.00386.x
  • Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32(6 Suppl 1):22–39. doi:10.1016/S0399-8320(08)73991-5
  • Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–350. doi:10.1053/j.gastro.2004.11.018
  • Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46(5):775–782. doi:10.1016/j.jhep.2006.12.013
  • Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat. 2006;13(10):659–670. doi:10.1111/j.1365-2893.2006.00736.x
  • Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi:10.1053/jhep.2003.50346
  • Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
  • Guido M, Rugge M. Liver fibrosis: natural history may be affected by the biopsy sample. Gut. 2004;53(12):1878.
  • Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13(3):372–374. doi:10.1016/0168-8278(91)90084-O
  • Kim SU, Jang HW, Cheong JY, et al. The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: a multicenter, prospective study. J Gastroenterol Hepatol. 2011;26(1):171–178. doi:10.1111/j.1440-1746.2010.06385.x
  • Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12(23):3682–3694. doi:10.3748/wjg.v12.i23.3682
  • Guha I, Rosenberg W. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis. 2008;12(4):883–900, x. doi:10.1016/j.cld.2008.07.010
  • Poynard T, Halfon P, Castera L, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem. 2007;53(9):1615–1622. doi:10.1373/clinchem.2007.085795
  • WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization Copyright © World Health Organization; 2015.
  • Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31(10):1095–1103. doi:10.1111/j.1365-2036.2010.04276.x
  • Boursier J, de Ledinghen V, Zarski JP, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2011;106(7):1255–1263. doi:10.1038/ajg.2011.100
  • Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int. 2013;7(2):356–368. doi:10.1007/s12072-013-9439-y